FDA Approves Daratumumab and Hyaluronidase-fihj for Multiple Myeloma

The FDA approved the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in adult patients with newly diagnosed or relapsed/refractory multiple myeloma.

Source: CancerNetwork - May 1, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news